Vyvanse for Binge Eating Disorder: What You Track

Session tracking for Vyvanse for binge eating disorder

Maya texts you at 7:40 a.m.: “The Vyvanse eating disorder thing is working. I barely wanted breakfast.” When a client takes Vyvanse for binge eating disorder, you are not the prescriber. You still have a job. Count binge days. Name appetite collapse in her words. Keep the hour on interruption of bingeing rather than on pounds. Send a short observation to the person who can change the medication.

For the hour that interrupts the binge, use eating disorder therapy techniques. Keep the standing team plan on the eating disorder treatment plan template.

Educational content for licensed therapists, not clinical or legal advice. Every medication decision belongs to the prescriber. You observe, ask, document, and pass on.

What the label actually approves

Lisdexamfetamine for binge eating is not a forum protocol. The VYVANSE label is the FDA source: a CNS stimulant indicated for ADHD in adults and in pediatric patients 6 years and older, and for moderate to severe binge eating disorder in adults. Two limitations sit on the same page. It is not recommended in children younger than 6. It is not indicated for weight loss, and other sympathomimetic drugs used for weight loss have been tied to serious cardiovascular events.

When a client asks whether Vyvanse for binge eating disorder is “the BED drug,” you can answer that adult moderate-to-severe BED is a labeled use. You cannot answer whether this client should start, stop, or stay on it.

The indication sits on two 12-week randomized trials in adults with protocol-defined moderate to severe BED. Lisdexamfetamine beat placebo on binge days per week. Dry mouth, insomnia, and headache were common. Pulse and blood pressure ticked up. That is why your note is a binge-day count plus the stimulant-class effects the client actually reported, not a story that the food noise is gone.

The label also tells the prescriber to stop the drug if binge eating does not improve. That sentence is not homework. If days are flat after the stretch the prescriber already named as a trial, you say they are flat.

What you track, and why it can fool you

Decreased appetite looks like progress in a BED hour until Thursday’s skipped lunch becomes Friday’s evening binge. Insomnia looks like “I’m finally getting things done” until the late-night window opens. Jitter looks like motivation until the client starts asking whether they should skip the Saturday dose so they can sleep.

You need a number you can hand off. Binge days this week. Binge episodes if the client can split them. One-line trigger (skipped lunch, evening collapse, conflict). Do not replace the diary with a once-a-quarter scale and call it tracking.

Watch the therapy frame. If Maya only wants to know what she weighed, the medication hour has eaten the treatment. Return to regular eating and the chain that precedes a binge.

Misuse talk is not a character judgment. The label lists Vyvanse as a CII stimulant and warns on abuse and dependence. “I left them at my sister’s,” “I ran out on Wednesday,” and “a friend asked if I had extras” are observations. Put them in a dated note on the team’s usual timeline.

What you ask each session

Keep the questions short enough that they fit before the work of the hour.

• How many days this week did a binge happen?
• Did you miss a morning dose, and which day?
• Did any planned meal get skipped because hunger vanished?
• What time did you fall asleep, and was that later than your usual?
• Any new edginess, crash, or thoughts that felt unlike you?
• Chest pain, faint, or shortness of breath?
• A pulse that felt newly fast?
• Anyone ask to borrow the capsules, or did the bottle run out early?

You are not taking a vital sign. You are asking what the client noticed, in their words, so the prescriber has more than “seems to be doing well.”

If the same client is also on a GLP-1, keep skipped-meal and binge observations on GLP-1 and binge eating rather than folding them into a Vyvanse success line. If the bottle was started for ADHD, or ADHD is sitting next to BED, send the pair to ADHD and eating disorders rather than collapsing two formulations into one “stimulant is working” line.

Download the documentation and treatment-planning pack to keep binge-day tracking, regular-eating work, and the prescriber handoff connected.

What you pass, and what you do not

Write observations. Do not write a suggested milligram. Do not write “consider increasing.” Do not interpret an ECG you have not seen.

A useful pass-on is dated, names the medication the client reports, gives binge-day counts, lists side effects in the client’s words, flags misuse talk, and states the therapy goal in behavioral terms.

The VYVANSE label tells patients to contact a healthcare provider right away for chest pain, shortness of breath, fainting, or new or worsening mental symptoms. Pass those the same day:

• Chest pain, shortness of breath, or fainting
• New or worsening mental symptoms, including hearing voices, believing things that are not real, or new mania

A newly fast pulse is a monitor item on the label, not a right-away example. Send it on the team’s usual timeline unless the prescriber has named a tighter rule.

Send a dated note on the team’s usual timeline for:

• Sharing, selling, or running out early
• Rapid restriction that the client describes as a medication success
• A pediatric client whose family is treating this as a BED prescription (the BED indication is adult)

If binge days have not moved and there is no same-day flag, send a dated note before the next med-check. Do not wait two more months to mention it.

Keep eating-disorder-focused psychotherapy in the hour. Medication can sit beside that plan. It does not replace it, and it does not turn you into the prescriber.

Keep the observation with the session record

Keep the observation next to the note, not in a parallel spreadsheet you forget to send. Emosapien can keep binge days, side-effect lines, and the prescriber handoff in the same session record.

References